Portfolio Opportunities Kurma Partners operates with two dedicated franchises, Biofund for therapeutics and Diagnostics for diagnostics and digital health, supported by two active funds (KBIII and Kurma Dx2). This structure creates a ready market for services to portfolio companies across drug development, regulatory, and manufacturing, as well as imaging and digital health solutions. Opportunities include CRO and CMO support for preclinical and clinical programs, regulatory pathway planning, and manufacturing partnerships; imaging analytics and AI driven radiology tools for Raidium and similar portfolio companies; and digital health data platforms to bolster diagnostic initiatives.

Fundraising Momentum Recent fundraising activity signals ongoing investor appetite and potential deal flow for portfolio growth. Biofund IV first close and continued fund management indicate Kurma's readiness to deploy capital across European health care startups, creating sales opportunities for services that support portfolio growth, from technical due diligence and clinical development roadmaps to regulatory prep and strategic partnerships.

Imaging Theranostics Active investments in imaging, radiopharmaceuticals, and theranostics, such as Raidium seed round, Nuclidium Series B, and Alveus Therapeutics financing, align with demand for imaging analytics platforms, radiology data solutions, and manufacturing partnerships for radiopharmaceutical programs.

Manufacturing Partnerships Kurma's collaboration with Samsung Biologics highlights openness to external manufacturing partnerships; this presents a pathway to offer CDMO services, process development, GMP manufacturing support, and scale up solutions to portfolio companies pursuing biologics, radiopharmaceuticals, or complex therapeutics.

Europe Market Access Based in Paris with a European focus and an international portfolio, Kurma can facilitate regulatory strategy, market access, and reimbursement planning across EU and US markets; there is an opportunity to partner with them on cross border clinical development, regulatory strategy, and strategic alliances that accelerate portfolio growth.